Non-small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of Epidermal Growth Factor Ointment for Patients With Erlotinib Related Skin Effects
Epidermal growth factor receptor-tyrosin kinase inhibitor (EGFR-TKI, Erlotinib) has
demonstrated its efficacy in patients with non-small cell lung cancer and pancreatic cancer.
But, their use is associated with dermatologic reactions of varying severity. Incidence of
Erlotinib related skin effect (ERSE) was reported ~75% in NSCLC and pancreatic cancer phase
III trials. Even though the dermatologic reactions could be a surrogated marker, it may be
cause of dose modification. Also, it could give significant physical and psycho-social
discomfort to patients. However, there is still a wide variety of drugs used- including,
steroid, antibiotics, and vitamin D without any clear evidence based management
recommendation.
The role of epidermal growth factor (EGF) has been extensively investigated in normal and
pathological wound healing. It is implicated in keratinocyte migration, fibroblast function
and the formation of granulation tissue. The first growth factor to be isolated growth
factor therapy has progressed into clinical practice in the treatment of wounds.
Therefore, the investigators propose an epidermal growth factor ointment apply for patients
with Erlotinib related skin effects.
Erlotinib
Advances in the knowledge of tumor biology and mechanisms of oncogenesis has granted the
singling out of several molecular targets for NSCLC treatment. Among these targets,
epidermal growth factor receptor (EGFR), or HER1, has received particular attention in lung
cancer treatment. EGFR is a transmembrane receptor found primarily on cells of epithelial
origin. Autophosphorylation of its intracellular domain initiates a cascade of events
leading to cell proliferation. EGFR is commonly expressed at a high level in a variety of
solid tumors and it has been implicated in the control of cell survival, proliferation,
metastasis and angiogenesis. The main pharmacological strategies in clinical development for
therapeutic inhibition of EGFR are monoclonal antibodies to antagonize ligand-receptor
binding, and small-molecules to inhibit tyrosine kinase domain activation. The main EGFR
inhibitors are cetuximab, an anti-EGFR monoclonal antibody, and Erlotinib an EGFRtyrosine
kinase inhibitor. The key indications for clinical use are colorectal cancer and head and
neck cancer for cetuximab and NSCLC for Erlotinib. Erlotinib, a quinazolin-4-amine, is a
highly potent, orally available, reversible inhibitor of EGFR tyrosine kinase. Erlotinib, in
a phase III randomized placebo-controlled trial, has been proven to prolong survival (6.7
months versus 4.7 months for Erlotinib and for placebo respectively, p = 0.001) in NSCLC
patients after first or second line chemotherapy. The analysis of quality of life and time
to deterioration of patients reported symptoms showed statistically and clinically
meaningful benefit for patients randomized to Erlotinib. Moreover, Erlotinib resulted active
(response rate of 8.9%) and safe (only 5% of patients discontinued treatment for toxicity).
Following this trial, Erlotinib has been approved by Food and Drug Administration and
Committee for Medicinal Products for Human use in chemotherapy-pretreated advanced NSCLC.
Skin rash is a common side-effect of all HER1/EGFR inhibitors.
EGF ointment
Rash affecting the skin above the waist, is the most common adverse event associated with
Erlotinib, and generally develops within 7-10 days of starting treatment. Skin rash may
spontaneously resolve and reappear and it is reversible following drug discontinuation.
However, when it develops, this chronic side-effect is very distressing for the patient. The
increasing use of EGFR-targeted agents and specifically of Erlotinib in NSCLC treatment, and
simultaneously the lack of clinical trials on this topic, makes rash management and etiology
investigation high priorities.
It has been reported that repeated treatment with EGF increases the epithelial cell
proliferation in a dose dependent manner and accelerates the wound healing process, whereas
a single EGF treatment has no noticeable effect on the wound-healing rate. There have been
many studies aimed at developing a topical formulation with the sustained and stable
pharmacological properties of recombinant human EGF (rhEGF). And the rh-EGF concentration
between 1 and 5 ug/g can be seen as the ideal concentration to achieve the most efficient
results for acute wounds with partial thickness defects.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |